glp-1 agonist indications GLP1 medicines now address weight loss and other health conditions through innovative formulations and expanded indications, highlighting key questions about their efficacy and safety. https://ja.ma/3JZg8l3 GLP-1 Agonists Market Report 2025-2033,

in vivo and in vitro studies

Obesity is more than a number on the scale: your fat cells act like mini chemical factories, pumping out molecules such as IL-6, TNF-alpha, and IL-17 that keep your immune system stuck in attack mode

[DOI] [PMC free article] [PubMed] [Google Scholar] 133.Rosenstock J, Wysham C, Fras JP, Kaneko S, Lee CJ, et al

The results of subgroup analysis showed that the interaction analysis of risk factors related to osteoporosis included gender, age, BMI, smoking and the use of antihypertensive drugs do not significantly affect the protective effect of GLP-1 RAs on osteoporosis

The same finding had been reported by a prior larger meta-analysis (6,914 patients with overweight or obesity and T2DM) over 8 studies 184,185,189,190,191,192,193,194 , but only when the largest study that also included non-diabetic participants 193 was excluded in a sensitivity analysis 195

Ozempic was (and still is) not FDA-approved for weight loss in patients without diabetes